Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.82 |
| ▸ | LMNA | P02545 | 4/20 | 0.82 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.82 |
| ▸ | RAB9A | P51151 | 10/20 | 0.71 |
| ▸ | NPC1 | O15118 | 10/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.71 |
| ▸ | MEN1 | O00255 | 6/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | TP53 | P04637 | 3/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.65 |
| ▸ | RELA | Q04206 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8712551 | 0.86 | MAPT (0.72) | MAPTLMNASETD7RAB9ANPC1 | |
| SCHEMBL16620958 | 0.83 | RAB9A (1.00) | MAPTLMNASETD7RAB9ANPC1 | |
| SCHEMBL10943066 | 0.81 | KMT2A (0.94) | MAPTLMNASETD7RAB9ANPC1 | |
| SCHEMBL6295679 | 0.80 | NPC1 (1.00) | MAPTLMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL108116 | 0.80 | NPC1 (1.00) | MAPTLMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL18941224 | 0.80 | NPC1 (0.72) | MAPTLMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL32690121 | 0.79 | MEN1 (1.00) | MAPTLMNASETD7RAB9ANPC1 | |
| SCHEMBL18300094 | 0.79 | MEN1 (1.00) | MAPTLMNASETD7RAB9ANPC1 | |
| SCHEMBL27179668 | 0.78 | RAB9A (0.90) | MAPTLMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL94830 | 0.78 | KMT2A (0.88) | MAPTLMNASETD7RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | MAPT 2167/4885LMNA 971/4885SETD7 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.